Nav: Home

Miriam first in New England to do completely laparoscopic robotic-assisted surgery for bladder cancer

October 12, 2016

PROVIDENCE, R.I. - The Minimally Invasive Urology Institute (MIUI) at The Miriam Hospital is now performing a completely laparoscopic surgery for the treatment of bladder cancer.

The procedure - robotic-assisted laparoscopic radical cystectomy with intracorporeal urinary diversion - can be used to remove the bladder, pelvic lymph nodes and prostate in men, and the bladder, uterus and fallopian tubes in women. The surgery concludes with removing a piece of bowel and using it to create a urinary diversion, or way for urine to leave the body in the absence of the bladder. The entire surgery is performed with an intracorporeal approach, meaning completely laparoscopically within the body, versus traditional open surgery.

Previously, the surgery was performed at The Miriam Hospital with a seven- to 10-centimeter incision at the belly button, and the urinary diversion was created through this incision, outside the body. Most other institutions still perform the surgery with a large incision in an open surgical approach. In addition to featuring smaller incisions, the minimally invasive intracorporeal approach offers improved patient outcomes, including a lower complication rate and shorter hospital stay, according to the International Robotic Cystectomy Consortium.

Dragan Golijanin, M.D., director of genitourinary oncology at The Miriam and Rhode Island hospitals and co-director of the MIUI, is among the first 11 urologists nationwide, and the only physician in New England, to have successfully performed a robotic cystectomy with intracorporeal urinary diversion. The first hospital in Southern New England to perform a robotic-assisted procedure, The Miriam has completed more than 2,000 urologic robotic-assisted surgeries since 2006.

"In being able to perform this difficult surgery laparoscopically from beginning to end, we are able to remain on the leading edge of bladder cancer treatments by offering patients the latest, most innovative care available. The result is improved outcomes for our patients. This further demonstrates our commitment to advanced urologic treatments," said Golijanin.

Cancer of the urinary bladder is the fifth most common cancer in Rhode Island, and the sixth most common in the United States. Bladder cancer also has the highest recurrence rate of any form of cancer. The most common symptom is blood in the urine, and a patient who experiences this should contact his or her physician immediately. Other symptoms include frequency, urgency, or pain while urinating.
About The Miriam Hospital

The Miriam Hospital is a 247-bed, not-for-profit teaching hospital affiliated with The Warren Alpert Medical School of Brown University. It offers expertise in cardiology, oncology, orthopedics, men's health, and minimally invasive surgery and is home to the state's first Joint Commission-certified Stroke Center and robotic surgery program. The first in Southern New England to perform robotic surgery and the only hospital in Rhode Island that offers a kidney stone center, The Miriam Hospital received more than $23 million in external research funding last year. It treats a range of urologic conditions and is one of three New England hospitals to offer blue-light cystoscopy for the diagnosis and treatment of bladder cancer. Named 2015-16 best regional hospital in Rhode Island and the Providence metro area by U.S. News & World Report, The Miriam Hospital has been awarded Magnet Recognition for Excellence in Nursing Services five times and is a founding member of the Lifespan health system. Follow us on Facebook, Twitter (@MiriamHospital and Pinterest.


Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#532 A Class Conversation
This week we take a look at the sociology of class. What factors create and impact class? How do we try and study it? How does class play out differently in different countries like the US and the UK? How does it impact the political system? We talk with Daniel Laurison, Assistant Professor of Sociology at Swarthmore College and coauthor of the book "The Class Ceiling: Why it Pays to be Privileged", about class and its impacts on people and our systems.